[Pubmed] Benefit of treatment with rituximab in autoimmune myasthenia gravis in children
Posté : 18 nov. 2024 12:00
Med Sci (Paris). 2024 Nov;40 Hors série n° 1:22-25. doi: 10.1051/medsci/2024132. Epub 2024 Nov 18.
ABSTRACT
The therapeutic management of autoimmune myasthenia gravis in children presents several particularities, which motivate the optimization of therapeutic management. On the one hand, corticosteroids are recommended as first-line immunosuppressive therapy, despite their significant adverse effects on growth, behavior, bone development, etc. On the other hand, in the absence of clinical trials in children, the place of promising new immunosuppressive therapies remains ill-defined. Rituximab is the non-steroidal immunosuppressant most widely used in France for autoimmune myasthenia gravis in children. Its use, without standardization of practices or monitoring of efficacy and safety, remains non-consensual. The aim of this study is to propose a new role for rituximab in the management of autoimmune myasthenia in children.
PMID:39555872 | DOI:10.1051/medsci/2024132
Source: https://pubmed.ncbi.nlm.nih.gov/3955587 ... t9+e462414